List view / Grid view
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
In this exclusive interview for World Hepatitis Day with Drug Target Review, Professor Ziv Ben Ari from the Sheba Medical Center discusses recent progress towards hepatitis treatment.
The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
The 2020 Nobel Prize in Physiology or Medicine has been bestowed upon researchers who helped identify the hepatitis C virus in the 1970s.
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
A new study has revealed five factors and proteins that hepatitis B infection needs for replication of its DNA, providing insight into the disease.
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients...
Researchers have made an important step forward in the design of drugs that fight the hepatitis B virus, which can cause liver failure and liver cancer...
28 November 2016 | By Niamh Louise Marriott, Digital Editor
This preclinical study should explore the potential of AIC649 to cure infections caused by hepatitis B virus (HBV) and is investigating the efficacy...
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
